Femasys Inc. (FEMY)
Nasdaq: FEMY · Surgical & Medical Instruments & Apparatus · Suwanee, GA · filing with the SEC since 2005
Who owns Femasys Inc.
As filed with the SECHolders of 5% or more
8
Nantahala Capital Partners Limited Partnership holds 9.99% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D filed Aug 17, 2026 says.
Directors and officers
11
report now, of 24 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
Nantahala Capital Partners Limited Partnership
SCHEDULE 13D · filed Aug 17, 2026 · Common Stock, $0.001 par value per share
Alumni Capital LP
SCHEDULE 13G · filed Sep 4, 2025 · Common Stock
Rosalind Advisors, Inc.
SCHEDULE 13G · filed Aug 14, 2026 · Common Shares
Dauntless Investment Group, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common · 5.4% in Feb 26, 2025
Chernett Jorey
SCHEDULE 13G/A · filed Aug 5, 2025 · Common · 6.2% in Feb 26, 2025
PharmaCyte Biotech, Inc.
SCHEDULE 13G · filed Mar 18, 2026 · Common Stock, par value $0.0001 per share
Stonepine Capital Management, LLC
SCHEDULE 13G · filed Aug 31, 2026 · Common Stock
Empery Asset Management, LP
SCHEDULE 13G · filed Oct 15, 2026 · Common Stock, $0.001 par value per share
What FEMY reports owning in othersstakes of 5% or more, and other ties
Femasys Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
5purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 25 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lee-Sepsick Kathy | Chief Executive Officer | 0 | $0 | 0 | 1 | $100,000 |
| Elefant Dov | Chief Financial Officer | 0 | $0 | 0 | 1 | $100,000 |
| Canning John Charles | Chief Operating Officer | 0 | $0 | 0 | 1 | $0 |
| Mifek Jeffrey Gerald | Chief Clinical-Medical Affairs | 0 | $0 | 0 | 1 | $0 |
| Sipos Jeremy Alexander | Chief Technology Officer | 0 | $0 | 0 | 1 | $0 |